BBA
Baker Bros. Advisors Portfolio holdings
AUM
$10.3B
This Quarter Return
+4.11%
1 Year Return
+63.34%
3 Year Return
+231.6%
5 Year Return
+293.68%
10 Year Return
+1,612.7%
AUM
$14.7B
AUM Growth
+$14.7B
(-0.1%)
Cap. Flow
+$64.6M
Cap. Flow
% of AUM
0.44%
Top 10 Holdings %
Top 10 Hldgs %
85.95%
Holding
111
New
8
Increased
15
Reduced
6
Closed
2
Top Buys
| 1 |
NVTA
Invitae Corporation
NVTA
|
$94.2M |
| 2 |
Acadia Pharmaceuticals
ACAD
|
$56.2M |
| 3 |
IGMS
IGM Biosciences
IGMS
|
$55.8M |
| 4 |
ALLK
Allakos
ALLK
|
$26.7M |
| 5 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
$26.1M |
Top Sells
| 1 |
ARRY
Array Biopharma Inc
ARRY
|
$132M |
| 2 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$94M |
| 3 |
Catalyst Pharmaceutical
CPRX
|
$6.46M |
| 4 |
BioCryst Pharmaceuticals
BCRX
|
$4.75M |
| 5 |
Insmed
INSM
|
$4.1M |
Sector Composition
| 1 | Healthcare | 93.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
AFMD
101
DELISTED
Affimed
AFMD
| $588K | ﹤0.01% |
200,000
| – | – |
|
|
EVFM
102
DELISTED
Evofem Biosciences, Inc. Common Stock
EVFM
| $514K | ﹤0.01% |
+102,048
| New | +$514K |
|
|
VIRX
103
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $401K | ﹤0.01% |
556,665
| – | – |
|
104
Aquestive Therapeutics
AQST
$478M
| $317K | ﹤0.01% |
99,600
| – | – |
|
105
Dynavax Technologies
DVAX
$1.19B
| $268K | ﹤0.01% |
75,000
| – | – |
|
|
TRIL
106
DELISTED
Trillium Therapeutics Inc.
TRIL
| $155K | ﹤0.01% |
505,262
| – | – |
|
107
Qualigen Therapeutics
QLGN
$2.95M
| $87K | ﹤0.01% |
279,999
| – | – |
|
|
ARRY
108
DELISTED
Array Biopharma Inc
ARRY
| – | – |
-2,848,567
| Closed | -$132M |
|
|
RNTX
109
Rein Therapeutics, Inc. Common Stock
RNTX
$29M
| – | – |
-2,040,000
| Closed | -$1.47M |
|